00:01 , May 11, 2019 |  BC Innovations  |  Translation in Brief

Arvinas, Palleon founders extend the reach of targeted degraders

A study from Arvinas founder Craig Crews is the second report in as many months of a technology geared to degrade extracellular proteins. The platforms open up new territory for targeted degradation therapies, on the...
08:00 , Feb 4, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: CXC chemokine receptor 7 (CXCR7)

Pulmonary disease INDICATION: Pulmonary Patient sample and mouse studies suggest agonizing CXCR7 could help treat lung fibrosis. Lung levels of CXCR7 were higher in patients with pulmonary fibrosis and a mouse model of bleomycin-induced lung...
08:00 , Dec 19, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Hepatic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Hepatic disease Liver fibrosis CXC chemokine receptor 4 (CXCR4; NPY3R); CXCR7 Mouse studies suggest agonizing CXCR7 or inhibiting CXCR4 could help prevent or treat liver fibrosis....
08:00 , Dec 19, 2013 |  BC Innovations  |  Targets & Mechanisms

Balancing act in liver fibrosis

CXCR7 , one of the few chemokine receptors against which there are virtually no drug development efforts, may be a novel target for liver fibrosis, according to new findings from a U.S. team. 1 The...
07:00 , Sep 26, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Head and neck cancer CXC chemokine receptor 7 (CXCR7) Mouse studies suggest CXCR7-targeting nanobodies could help treat head and neck cancers....
08:00 , Feb 13, 2012 |  BC Week In Review  |  Clinical News

CCX832: Development discontinued

ChemoCentryx disclosed in an SEC filing that it and partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.) will discontinue development of CCX832 and its 2 backup compounds. ChemoCentryx said the decision was based on unblinded data...
08:00 , Feb 9, 2012 |  BC Innovations  |  Targets & Mechanisms

HUS and them

Two groups have identified new strategies to treat or prevent hemolytic uremic syndrome, a potentially lethal complication of Escherichia coli infection. A team at the University of Toronto has suggested that the marketed CXC chemokine...
01:11 , Feb 7, 2012 |  BC Extra  |  Clinical News

ChemoCentryx, GSK discontinue ChemR23 antagonist

ChemoCentryx Inc. (Mountain View, Calif.) said it and partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) will discontinue development of CCX832 and its two backup compounds. ChemoCentryx said the decision was based on unblinded data from a Phase...
08:00 , Jan 19, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Hematology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Hematology Hemolytic uremic syndrome CXC chemokine receptor 4 (CXCR4; NPY3R); chemokine CXC motif ligand 12 (CXCL12; SDF-1); CXCR7 In vitro and mouse...
08:00 , Mar 3, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Autoimmune disease Multiple sclerosis (MS) CXC chemokine receptor 7 (CXCR7) Mouse studies suggest that antagonizing CXCR7 could help treat MS. In...